Editorial: antigenic response to CT-P13 and infliximab originator in IBD shows similar epitope recognition—evidence from basic science supports safe switching to biosimilars. Authors’ reply

J. Goncalves, F. Magro, S. Danese, P. L. Lakatos, S. Ben-Horin

Research output: Contribution to journalEditorial

Original languageEnglish
Pages (from-to)575-576
Number of pages2
JournalAlimentary Pharmacology and Therapeutics
Issue number5
StatePublished - Sep 2018

Cite this